Potential Risks
The method of convalescent PT has been used daily in many hospitals for years. Convalescent PT against SARS-Cov-2 differs from standard plasma only in the presence of neutralizing antibodies directed against Sars-Cov-2, therefore the transfusion risks could be considered not different from those of standard plasma. An open question could be the risk of infection transmission. In COVID-19 patients this should obviously not be considered because they are already infected, but in the case of prophylactic use yes. However, these are theoretical risks, as no transmission of respiratory infection has ever been reported. viral by plasma transfusion. SARS-CoV-2 is probably not considered a relevant transfusion virus of infection.(21-22). However, it should be considered that donors will have to meet certain requirements, such as waiting a few weeks after the resolution of their symptomatology and above all must also be negative for SARS-CoV-2, determined by diagnostic molecular tests.